Who to call at Aarvik Therapeutics, and when
Fundz watches for the moments Aarvik Therapeutics starts buying, and tells you who to reach.
- An alert the day Aarvik Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aarvik Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aarvik Therapeutics. With Fundz connected, it knows.
Aarvik Therapeutics Enters Partnership with Laurus Labs for MUTTA™ ADC Development in India.
Contract Type
partnership
HaywardBiotechnologyHealthcareHealth CareTherapeuticsresearchDescription
Aarvik Therapeutics has announced a license agreement with Laurus Labs for the development and commercialization of two MUTTA™ ADC molecules in India. Aarvik retains all rights to these molecules outside of India, aiming to leverage Laurus Labs' expertise in manufacturing and commercialization for rapid clinical progress.
Quick answer
Aarvik Therapeutics Enters Partnership with Laurus Labs for MUTTA™ ADC Development in India. (November 3, 2026). Aarvik Therapeutics is based in Hayward, California, United States.
- What agreement did Aarvik Therapeutics announce on November 3, 2026?
- Aarvik Therapeutics has announced a license agreement with Laurus Labs for the development and commercialization of two MUTTA™ ADC molecules in India. Aarvik retains all rights to these molecules outside of India, aiming to leverage Laurus Labs' expertise in manufacturing and commercialization for rapid clinical progress.
- What does Aarvik Therapeutics do?
- Aarvik Therapeutics is pursuing exciting, novel molecules with an improved therapeutic index for several oncology targets by combining a novel modular antibody platform with multiple target mechanisms.
- Where is Aarvik Therapeutics based?
- Aarvik Therapeutics is based in Hayward, California, United States.
- Which similar companies announced agreements around the same time?
- AbbVie Inc. (November 3, 2026), Ocugen (November 10, 2026), Teva Pharmaceutical Industries Ltd (November 3, 2026) and Kimia Therapeutics (November 5, 2026) also announced agreements within 45 days of Aarvik Therapeutics.
Source: Fundz verified event record.
Other recent agreements in Healthcare and Therapeutics
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- AbbVie partners with McLaren Racing in a multiyear collaboration to promote liver health awareness through Formula 1. (November 3, 2026)
- Ocugen Enters Exclusive License Agreement with Celairis Therapeutics (November 10, 2026)
- Teva and Samsung Bioepis Sign Agreement for U.S. Rights to Biosimilars Infliximab and Etanercept. (November 3, 2026)
- Kimia Therapeutics and CStone Pharmaceuticals Collaborate on Clinical Development of KT-721 for Oncology Treatment. (November 5, 2026)
- BioMarin Enters Exclusive License Agreement With GC Biopharma and Hanmi Pharm for HM15421/GC1134A to Treat Fabry Disease. (October 29, 2026)
- Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years. (October 29, 2026)
Related People
Agreement Insights
What this usually meansAarvik Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.